T
he Rh blood group system (ISBT004) is one of the most complex blood group systems. It includes five major antigens (D, C, c, E, and e), encoded by two highly homologous genes, RHD and RHCE, respectively. From the 1 protein. 3, 4 At present (July 2018), 170 different weak D alleles have been described. 5 The molecular events underlying these weak D and partial D include missense mutations, insertions, deletions of the RHD gene, or RHD-CE-D hybrid alleles. 6 In rare cases, mutations in genes encoding proteins required for proper membrane expression of Rh proteins, such as Rh-associated glycoprotein (RhAG) 7, 8 and ankyrin 1, 9, 10 can also lead to absent or weakened expression of Rh antigens. The RhAG antigen is essential for the normal expression of RhD and RhCE antigens on the surface of the red blood cell (RBC) membrane. 11 Mutations of the RHAG gene were reported to result in complete absence (Rh null phenotype) [12] [13] [14] [15] [16] or severe reduction (Rh mod phenotype) 17, 18 of the expression of Rh antigens on the RBC membrane. In addition, ankyrin 1 was recognized as a structural adaptor protein that links membrane proteins to the cytoskeleton 19 and mutations in the ANK1 gene were reported to result in reduced expression of Rh polypeptides. 9 In this study, we describe for the first time a weak D phenotype with normal RhCE expression that is not caused by a mutant RHD allele but is the consequence of a homozygous RHAG*572A allele resulting in a normally expressed RhAG antigen harboring a Arg191Gln mutation. The RHAG*572A allele was identified in a Chinese donor. Further expression studies in vitro confirmed that the encoded RhAG-Arg191Gln substitution resulted in weak expression of D antigen but normal expression of RhAG and RhCE antigens.
MATERIALS AND METHODS

Sample and RhD and RhCE serological typing
A peripheral blood sample of the D variant donor was collected from the Guangzhou Blood Center in China. Genomic DNA was extracted from the peripheral blood sample using the Blood DNA Midi Kit (Omega Bio-tek). This study was approved by the Ethics Committee of the Guangzhou Blood Center.
The RhD antigen was first routinely typed by a monoclonal anti-D reagent (Clone Rum-1, immunoglobulin [Ig] M; Shanghai Hemo-Pharmaceutical & Biological Co.) on a PK7300 blood grouping analyzer system (Beckman Coulter), and it was further tested using another anti-D reagent (Clone TH-28/MS-26, IgM/IgG, Millipore) and a commercial panel of monoclonal anti-D reagents (D-Screen; Diagast) by a tube agglutination method for IgM antibodies or an indirect antiglobulin test with DG Gel Coombs card (Diagnostic Grifols) for IgG antibodies. The RhCE antigens were typed using the following antibodies: two different anti-C (clone MS-24, Sanquin Reagents, and clone P3 × 25513 G8, Diagast); anti-c (clone MS-33, Sanquin Reagents); anti-E (clone MS-26, Sanquin Reagents); and two different anti-e (clone MS-16/MS-21/MS-63, Millipore); and clone P3GD512/MS63, Diagast) by the tube agglutination method.
RH-MLPA genotyping and sequencing of the RHD gene
The RHD and RHCE genotypes were analyzed by the RH-MLPA assay as described previously. 20 All 10 coding exons and the promoter region of the RHD gene were amplified using the primers and conditions as described previously, 21, 22 and polymerase chain reaction products were further analyzed by Sanger sequencing.
Next-generation sequencing analysis of the RHAG and ANK1 genes 
In vitro transduction and flow cytometry analysis
The coding sequences of wild-type (wt) RHD and wt RHCE*ce were cloned into pHeftig lentiviral vector containing IRES-GFP for bicistronic gene expression. The coding sequence of wt RHAG was cloned into pSINK lentiviral vector using XbaI and NheI restriction sites; the missense mutation (c.572G > A) was introduced into the wt RHAG construct by using the mutagenic primers 
RESULTS
Serological typing identified a weak D phenotype with normal RhCE antigen expression in a Chinese donor
The donor was initially identified as D negative using IgM anti-D (Clone Rum-1) by routine RhD serological typing on the PK7300 blood grouping analyzer system. Further typing showed that the RBCs of this donor had weak agglutination (2+ agglutination strength) in saline using the tube method and strong agglutination (4+) in the indirect antiglobulin test with another IgM/IgG anti-D reagent (Clone TH-28/ MS-26). When typed using a panel of anti-D reagents (DScreen), the RBCs showed weak agglutination with all nine different anti-D antibodies, which indicates this donor has a serological weak D phenotype (Table S1 , available as supporting information in the online version of this paper). In addition, a normal C + c-E-e + phenotype was identified in this donor (Table S1 ).
Normal CCDDee genotype but homozygous RHAG*572A allele identified in the donor transmembrane domain, 23 which was further confirmed by Sanger sequencing (Fig. S1 , available as supporting information in the online version of this paper).
The RHAG*572A allele does not lead to lowered RhAG expression Flow cytometry analysis using two different anti-RhAG monoclonal antibodies showed no obvious difference in RhAG antigen expression in the donor having the homozygous RHAG*572A allele compared with the controls having the normal RhAG expression and the same Rh phenotype (D + C + c-E-e+) (n = 3) (Fig. 1) . This finding suggests the RHAG*572A allele and the resulting RhAG-Arg191Gln do not influence the expression of the RhAG antigen.
In vitro transduction analysis of RhAG and Rh antigens in HEK 293 T cells
To confirm the effect of the homozygous RHAG*572A allele on the expression of RhAG, RhD, and RhCE antigens, in vitro transduction and expression analysis were performed. First, HEK 293 T cells were lentivirally transduced with wt RHAG construct and mutant RHAG*572A construct, respectively. The flow cytometry result showed virtually identical levels of RhAG expression on the HEK 293 T cells upon staining with antiRhAG (Clone 2D10) ( Fig. 2A) . This suggests that the RHAG*572A allele does not influence the expression of RhAG antigen in vitro, which was also consistent with the normal RhAG expression obtained on the donor's RBCs. Next, 1) wt RHAG and wt RHD constructs, 2) wt RHAG and wt RHCE*ce constructs, 3) mutant RHAG*572A and wt RHD constructs, and 4) mutant RHAG*572A and wt RHCE*ce constructs were lentivirally co-transduced into HEK 293 T cells to confirm the effect of the RHAG*572A on the expression of D, c, and e antigens. RhD antigen expression was significantly decreased in the cells co-transduced with mutant RHAG*572A and wt RHD constructs compared with the cells co-transduced with wt RHAG and wt RHD constructs (Fig. 2B) . In contrast, similar c and e antigen expression was detected in the cells cotransduced with mutant RHAG*572A and wt RHCE*ce constructs compared with the cells co-transduced with wt RHAG and wt RHCE constructs (Figs. 2C, 2D ). The expression data were also in agreement with RhD and RhCE serological typing results obtained in the donor (Table S1 ). These results indicate that the homozygous RHAG*572A allele is responsible for weakened expression of RhD antigen, although it does not affect the expression of RhCE antigens.
DISCUSSION
In this study, a homozygous RHAG*572A allele but normal sequence of the RHD gene was identified in a Chinese donor having a serological weak D but normal C + c-E-e + phenotypes. This mutation had been annotated as rs550840907 and is almost exclusively present in Asian individuals with an allele frequency for East Asians of 0.004275 and for South Asians of 0.0001817 in the ExAc database (see Web Resources). In an abstract, Tsuneyama and colleagues were the first to identify this RHAG*572A allele in five Japanese donors with a serological weak D phenotype but normal RhAG level. 24 The allele was previously assigned by the and RhCE antigens by complete or partial failure of the assembly of the Rh core complex. Interestingly, the Arg191 is highly conserved among the three human ammonium transporters RhCG, RhBG, and RhAG, and it is also present in a conserved region (LYRR) in all Rh, Amt, and MEP proteins. 27 Although the Arg191Gln mutation in the third intracellular loop of RhAG was predicted to be damaging according to silico algorithms at the wANNOVAR website (SIFT, Polyphen, MutationTaster, MutationAssessor, CADD, and FATHMM), both serological and flow cytometry analysis on primary RBCs as well as in vitro expression results showed that the RHAG*572A allele did not affect the surface expression of the RhAG antigen. The donor had a serological weak D but a normal C + c-E-e + phenotype rather than the Rh null or Rh mod phenotype, and further in vitro expression studies also confirmed that RHAG*572A allele only affected the RhD antigen and not the RhCE antigens. Thus, unlike previously reported RHAG mutations that affected both RhD and RhCE antigens, [12] [13] [14] [15] [16] [17] [18] RHAG*572A resulting in Arg191Gln only affects the RhD antigen. This Arg191Gln mutation does not affect the assembly with the RhCcEe polypeptides. This was shown for the Ce polypeptide on the RBCs of the Chinese donor as well as for the ce polypeptide in the in vitro transduction studies. Because the E and e polypeptides only differ in the fourth extracellular loop of the RhCcEe polypeptide, an effect on the assembly of RhAG and RhcE or RhCE antigens is not expected, but this has not been proven formally as yet. In Fig. 3 , the position of Arg191 in the hypothetical model of RhD-RhAG 2 based on the crystallographic structure of the human RhCG trimer is shown. 27 According to this model, Arg191 is not located at the interphases between the Rh proteins in the complex, but is in fact even quite far away from it, which makes it difficult to explain how the mutation interferes with RhD expression. However, the adjacent amino acids in the model are also charged amino acids, so it seems plausible that the loss of the positively charged Arg will result in a change in the cytoplasmic surface of the RhAG antigen. We hypothesize that this structural change may interfere with the interaction of a cytoplasmic protein. Possibly this protein is ankyrin 1 because this protein is needed for the correct assembly of the trimeric complex containing RhD, 9 but future research is needed to explain the finding that mutations far from the Rh-RhAG interphase can interfere only with RhD expression. Very recently, another RHAG mutation was described that, similar to the Arg191Gln substitution, has more effect on RhD expression than on RhCE expression. 28 The heterozygous presence of RHAG*236A was shown to result in spherocytosis, lowered RhAG and RhCE expression, and D-negativity (although the DEL phenotype was not excluded). The 236G > A mutation results in a Ser79Arg substitution near the cytosolic end of an outer transmembrane alpha-helix and might, therefore, in contrast to the Arg191Gln substitution described in the present article, interfere with the RhAG-RhAG and RhAG-RhD assembly. The differential effect of RHAG mutations on RhD and RhCE expression indicates structural differences between RhD and RhCE complexes, and it can serve as the basis for further studies of the RhD-RhAG interaction and assembly of Rh complex.
In conclusion, a missense mutation in the RHAG gene, which did not affect the expression of RhAG, can result in weak D and normal expression of RhCE antigens. Our results may provide possible insights into the further studies of the RhD-RhAG interaction and assembly of the Rh complex, and confirm previous findings that in NGS-based assays for genetic analysis of individuals with weakened Rh expression, RHAG and, preferably, also ANK1 have to be included. Table S1 . Reactivity patterns with the different antibodies in the donor carried RHAG*572A. Table S2 . List of submitted genes and the coverage of the designed next-generation sequencing AmpliSeq panel. Table S3 . List of primers in the designed next-generation sequencing AmpliSeq panel targeting RHAG, SCL4A1, EPB42, and ANK1.
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